CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine

CurifyLabs, a health technology company focused on revolutionizing the production of personalized medications, has successfully closed a $14 million Series A funding round. The financing was co-led by Sandwater and HealthCap, with additional participation from Tesi and existing investors, including Lifeline Ventures. The announcement was made on July 6, 2026, and the funds will be utilized to bolster U.S. operations, enhance supply chain infrastructure, and accelerate research and development efforts.

Founded in 2021, CurifyLabs has developed an innovative Compounding System Solution (CSS) that integrates proprietary software with GMP-manufactured excipients and advanced 3D printing technology. This system automates the preparation of personalized medications, allowing pharmacies to produce tailored doses with greater precision and efficiency compared to traditional manual compounding methods. Currently, CurifyLabs' technology is employed by pharmacies across 21 U.S. states and Europe, compounding and dispensing thousands of doses daily.

The strategic rationale behind this funding round is clear: as the demand for personalized medicine continues to grow, CurifyLabs aims to enhance its operational capabilities to meet this rising need. The investment will not only support the expansion of its U.S. footprint but also strengthen the supply chain to ensure that pharmacy partners have timely access to the necessary resources. This is particularly critical as the company seeks to scale its operations and solidify its position in a competitive market.

The health technology sector is experiencing significant growth, driven by advancements in personalized medicine and increasing recognition of its potential to improve patient outcomes. Investors like Sandwater and HealthCap recognize the transformative potential of CurifyLabs' technology, which combines clinical rigor with operational efficiency. As noted by industry experts, the ability to deliver personalized therapies safely and efficiently is becoming increasingly important in the healthcare landscape.

Looking ahead, the successful completion of this funding round positions CurifyLabs for continued growth and innovation in the personalized medicine space. With the backing of prominent investors and a commitment to enhancing its technology and support systems, CurifyLabs is well-equipped to capitalize on the expanding market opportunities. The ongoing development of its products, including the PharmaPrinter Aurum, which boasts a compounding speed up to nine times faster than traditional methods, underscores the company's potential to redefine the standards of personalized medication delivery in the health technology sector.